ArticleJournal of Crohn's & colitis2022

Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].

Esther Ventress et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.